Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

The Lancet Neurology

Volumn 15, Issue 10, 2016, Pages 1044-1053

  Burnham, Samantha C ^a   Bourgeat, Pierrick ^a   Doré, Vincent ^a,b   Savage, Greg ^c   Brown, Belinda ^d   Laws, Simon ^d,e   Maruff, Paul ^f   Salvado, Olivier ^a   Ames, David ^g   Martins, Ralph N ^d,h   Masters, Colin L ^g   Rowe, Christopher C ^g   Villemagne, Victor L ^b,g  

^a CSIRO   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f Scientific Division   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; FLORBETAPIR F 18; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; CANCER SIZE; CARDIOVASCULAR RISK; CEREBROSPINAL FLUID; COGNITION; DISEASE COURSE; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENOTYPE; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUSPECTED NON ALZHEIMER'S DISEASE PATHOPHYSIOLOGY; VERBAL MEMORY; WHITE MATTER; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; LONGITUDINAL STUDY; METABOLISM; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PRODROMAL SYMPTOMS;

EID: 84979547145     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30125-9     Document Type: Article

References (33)

1. 1 Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
2. 2 Albert, MS, DeKosky, ST, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
3. 3 McKhann, GM, Knopman, DS, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
4. 4 Jack, CR, Knopman, DS, Weigand, SD, et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.
5. 5 Knopman, D, Jack, C, Wiste, H, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78 (2012), 1576–1582.
6. 6 Mormino, EC, Betensky, RA, Hedden, T, et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
7. 7 Vos, SJ, Xiong, C, Visser, PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12 (2013), 957–965.
8. 8 van Harten, AC, Smits, LL, Teunissen, CE, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81 (2013), 1409–1416.
9. 9 Vos, SJ, Verhey, F, Frölich, L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338.
10. 10 Petersen, RC, Aisen, P, Boeve, BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74 (2013), 199–208.
11. 11 Prestia, A, Caroli, A, van der Flier, WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80 (2013), 1048–1056.
12. 12 Jack, CR, Therneau, TM, Wiste, HJ, et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 15 (2016), 56–64.
13. 13 McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM, Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34 (1984), 939–944.
14. 14 Winblad, B, Palmer, K, Kivipelto, M, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256 (2004), 240–246.
15. 15 Ellis, KA, Bush, AI, Darby, D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21 (2009), 672–687.
16. 16 Rowe, CC, Ellis, KA, Rimajova, M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31 (2010), 1275–1283.
17. 17 Wong, DF, Rosenberg, PB, Zhou, Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 51 (2010), 913–920.
18. 18 Vandenberghe, R, Van Laere, K, Ivanoiu, A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68 (2010), 319–329.
19. 19 Thurfjell L, Lundqvist R, Buckley C, Smith A, Sherwin P. Automated quantification of [18F] flutemetamol data-Comparison with standard of truth based on histopathology. Society of Nuclear Medicine Annual Meeting Abstracts; Vancouver, BC, Canada; June 8–12, 2013. p 302.
20. 20 Clark, CM, Pontecorvo, MJ, Beach, TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11 (2012), 669–678.
21. 21 Villemagne, VL, Burnham, S, Bourgeat, P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12 (2013), 357–367.
22. 22 Boccardi, M, Bocchetta, M, Morency, FC, et al. Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol. Alzheimers Dement 11 (2015), 175–183.
23. 23 Schmidt, P, Gaser, C, Arsic, M, et al. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 59 (2012), 3774–3783.
24. 24 Bernal-Rusiel, JL, Greve, DN, Reuter, M, Fischl, B, Sabuncu, MR, Alzheimer's Disease Neuroimaging Initiative. Statistical analysis of longitudinal neuroimage data with linear mixed effects models. Neuroimage 66 (2013), 249–260.
25. 25 Pinheiro, JC, Bates, DM, Linear mixed-effects models: basic concepts and examples. Mixed-Effects Models in S and S-Plus, 2000, Springer, New York, 3–56.
26. 26 Azur, MJ, Stuart, EA, Frangakis, C, Leaf, PJ, Multiple imputation by chained equations: what is it and how does it work?. Int J Methods Psychiatr Res 20 (2011), 40–49.
27. 27 Elias, MF, Beiser, A, Wolf, PA, Au, R, White, RF, D'Agostino, RB, The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol 57 (2000), 808–813.
28. 28 Grober, E, Hall, CB, Lipton, RB, et al. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14 (2008), 266–278.
29. 29 Derby, CA, Burns, LC, Wang, C, et al. Screening for predementia AD time-dependent operating characteristics of episodic memory tests. Neurology 80 (2013), 1307–1314.
30. 30 Mormino, EC, Betensky, RA, Hedden, T, et al. Amyloid and APOE ɛ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82 (2014), 1760–1767.
31. 31 Lim, YY, Villemagne, VL, Pietrzak, RH, et al. APOE ɛ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiol Aging 36 (2015), 1239–1244.
32. 32 Petersen, RC, Wiste, HJ, Weigand, SD, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 73 (2016), 85–92.
33. 33 Rowe, CC, Bourgeat, P, Ellis, KA, et al. Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74 (2013), 905–913.